Skip to content

Clinical trials

Phase 2 Neurocognitive Disorders trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Neurocognitive Disorders Phase: Phase 2 Country / region: United States Clear all

14 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20151
20172
20182
20191
20201
20211
20231
20252
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed6
Recruiting3
Enrolling by invitation1
Active, not recruiting1
Suspended1
Terminated1
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Alkahest, Inc.3
MapLight Therapeutics2
EIP Pharma Inc1
Eastern Virginia Medical School1
Eli Lilly and Company1
Genentech, Inc.1
Johns Hopkins University1
National Institute of Allergy and Infectious Diseases (NIAID)1
Sheppard Pratt Health System1
Tetra Discovery Partners1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Neurocognitive Disorders14
Brain Diseases9
Nervous System Diseases8
Neurodegenerative Diseases8
Alzheimer Disease7
Central Nervous System Diseases7
Dementia7
Mental Disorders7
Cognitive Dysfunction4
Tauopathies3

Trials

Showing 1 to 14 of 14. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.